OCGN
Ocugen Inc. Healthcare - Biotechnology Investor Relations →
Ocugen Inc. (OCGN) closed at $2.04 as of 2026-03-20, trading 74.0% above its 200-week moving average of $1.17. The stock is currently moving closer to the line, down from 111.3% last week. The 14-week RSI sits at 62, indicating neutral momentum.
A big spike in selling this week — 2.7x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 541 weeks of data, OCGN has crossed below its 200-week moving average 2 times. On average, these episodes lasted 260 weeks. The average one-year return after crossing below was -36.1%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $669 million, OCGN is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -776.9%. The stock trades at -52.3x book value.
Share count has increased 41.0% over three years, indicating dilution.
Over the past 10.4 years, a hypothetical investment of $100 in OCGN would have grown to $1, compared to $370 for the S&P 500. OCGN has returned -35.4% annualized vs 13.4% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: OCGN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After OCGN Crosses Below the Line?
Across 2 historical episodes, buying OCGN when it crossed below its 200-week moving average produced an average return of -40.0% after 12 months (median -40.0%), compared to +8.0% for the S&P 500 over the same periods. After 24 months, the average return was -38.0% vs +32.0% for the index.
Each line shows $100 invested at the moment OCGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
OCGN has crossed below its 200-week MA 2 times with an average 1-year return of +-36.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 2015 | Sep 2025 | 515 | 99.7% | -36.1% | -99.1% |
| Nov 2025 | Dec 2025 | 4 | 9.9% | N/A | +71.4% |
| Average | 260 | — | +-36.1% | — |
Frequently Asked Questions
Is OCGN below its 200-week moving average?
No. Ocugen Inc. (OCGN) is currently 74.0% above its 200-week moving average of $1.17. It would need to fall to $1.17 to cross below the line.
What is OCGN's 200-week moving average price?
Ocugen Inc.'s 200-week moving average is $1.17 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when OCGN drops below its 200-week moving average?
OCGN has crossed below its 200-week moving average 2 times in our data. The average one-year return after these crossings was -36.1%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 260 weeks on average.
Is OCGN a good value right now?
Here's what our data says about OCGN as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 62. Free cash flow is currently negative. Return on equity is -776.9%. Price-to-book is -52.3x. This is not a buy or sell recommendation — always do your own research.
How does OCGN compare to the S&P 500?
Over the past 10.4 years, $100 invested in OCGN would have grown to $1, compared to $370 for the S&P 500. That's -35.4% annualized vs 13.4% for the index. OCGN has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20